Stay updated on Taldefgrobep Alfa in SMA Clinical Trial
Sign up to get notified when there's something new on the Taldefgrobep Alfa in SMA Clinical Trial page.

Latest updates to the Taldefgrobep Alfa in SMA Clinical Trial page
- ChecktodayChange DetectedRevision label updated from v3.5.3 to v3.5.4, indicating the page has been republished with a new version. This generally reflects minor edits or clarifications to the displayed study information rather than new study results.SummaryDifference0.0%

- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedThe page’s revision was updated to v3.5.3, replacing v3.5.2, indicating a minor update to the Study Details page.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedRevision history updated: added v3.5.2 and removed v3.5.0.SummaryDifference0.0%

- Check58 days agoChange DetectedRevision: v3.4.3 updated to v3.5.0.SummaryDifference0.0%

- Check65 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3. No other content or functionality appears to be affected.SummaryDifference0.0%

- Check93 days agoChange DetectedAdded detailed extension phase dosing for taldefgrobep alfa and placebo, including open-label extension (OLE) phase. Updated the protocol to version 3.4.2 with related update dates (2026-01-30, 2026-02-04, 2026-06).SummaryDifference0.5%

Stay in the know with updates to Taldefgrobep Alfa in SMA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Taldefgrobep Alfa in SMA Clinical Trial page.